Literature DB >> 25620899

PSYCHIATRIC DISORDERS ASSOCIATED WITH FXTAS.

Andreea L Seritan1, Melina Ortigas2, Stefan Seritan3, James A Bourgeois4, Randi J Hagerman5.   

Abstract

Carriers of the FMR1 premutation (with 55-200 CGG repeats) may present with multiple medical and psychiatric disorders. Middle-aged carriers (males more often than females) may suffer from fragile X-associated tremor/ataxia syndrome (FXTAS). FXTAS is a newly discovered neurodegenerative disease characterized by intention tremor and ataxia, along with several other neurological features. Psychiatric manifestations are common in premutation carriers of both genders and include attention deficits, anxiety, depression, irritability, impulse dyscontrol, and substance abuse or dependence. Major depressive disorder, panic disorder with or without agoraphobia, generalized anxiety disorder, social phobia, and specific phobia are among the psychiatric diagnoses often encountered in premutation carriers, including those with FXTAS. Later in the course of the illness, cognitive deficits (including dementia) may occur. In this paper, we discuss common psychiatric phenotypes in FXTAS, based on a thorough review of the literature, as well as our own research experience. Symptomatic pharmacologic treatments are available, although disease modifying agents have not yet been developed.

Entities:  

Keywords:  FMR1 premutation; FXTAS; anxiety; depression; psychiatric disorders; substance abuse

Year:  2013        PMID: 25620899      PMCID: PMC4304643          DOI: 10.2174/157340013805289699

Source DB:  PubMed          Journal:  Curr Psychiatry Rev        ISSN: 1573-4005


  56 in total

1.  Symptomatic treatment in the fragile X-associated tremor/ataxia syndrome.

Authors:  Deborah A Hall; Elizabeth Berry-Kravis; Randi J Hagerman; Paul J Hagerman; Cathlin D Rice; Maureen A Leehey
Journal:  Mov Disord       Date:  2006-10       Impact factor: 10.338

2.  The fragile X prevalence paradox.

Authors:  Paul J Hagerman
Journal:  J Med Genet       Date:  2008-04-15       Impact factor: 6.318

3.  Autism spectrum disorders and attention-deficit/hyperactivity disorder in boys with the fragile X premutation.

Authors:  Faraz Farzin; Hazel Perry; David Hessl; Danuta Loesch; Jonathan Cohen; Susan Bacalman; Louise Gane; Flora Tassone; Paul Hagerman; Randi Hagerman
Journal:  J Dev Behav Pediatr       Date:  2006-04       Impact factor: 2.225

4.  Abnormal elevation of FMR1 mRNA is associated with psychological symptoms in individuals with the fragile X premutation.

Authors:  David Hessl; Flora Tassone; Danuta Z Loesch; Elizabeth Berry-Kravis; Maureen A Leehey; Louise W Gane; Ingrid Barbato; Cathlin Rice; Emma Gould; Deborah A Hall; James Grigsby; Jacob A Wegelin; Susan Harris; Foster Lewin; Dahlia Weinberg; Paul J Hagerman; Randi J Hagerman
Journal:  Am J Med Genet B Neuropsychiatr Genet       Date:  2005-11-05       Impact factor: 3.568

5.  Expanded clinical phenotype of women with the FMR1 premutation.

Authors:  Sarah M Coffey; Kylee Cook; Nicole Tartaglia; Flora Tassone; Danh V Nguyen; Ruiqin Pan; Hannah E Bronsky; Jennifer Yuhas; Mariya Borodyanskaya; Jim Grigsby; Melanie Doerflinger; Paul J Hagerman; Randi J Hagerman
Journal:  Am J Med Genet A       Date:  2008-04-15       Impact factor: 2.802

6.  Impact of the Fragile X mental retardation 1 (FMR1) gene premutation on neuropsychiatric functioning in adult males without fragile X-associated Tremor/Ataxia syndrome: a controlled study.

Authors:  Cary S Kogan; Jeremy Turk; Randi J Hagerman; Kim M Cornish
Journal:  Am J Med Genet B Neuropsychiatr Genet       Date:  2008-09-05       Impact factor: 3.568

7.  Evidence of depressive symptoms in fragile-X syndrome premutated females.

Authors:  Laia Rodriguez-Revenga; Irene Madrigal; Montserrat Alegret; Mónica Santos; Montserrat Milà
Journal:  Psychiatr Genet       Date:  2008-08       Impact factor: 2.458

Review 8.  Interaction between BDNF and serotonin: role in mood disorders.

Authors:  Keri Martinowich; Bai Lu
Journal:  Neuropsychopharmacology       Date:  2007-09-19       Impact factor: 7.853

Review 9.  Efficacy of exposure versus cognitive therapy in anxiety disorders: systematic review and meta-analysis.

Authors:  Dennis Ougrin
Journal:  BMC Psychiatry       Date:  2011-12-20       Impact factor: 3.630

Review 10.  Treatment of fragile X-associated tremor ataxia syndrome (FXTAS) and related neurological problems.

Authors:  Randi J Hagerman; Deborah A Hall; Sarah Coffey; Maureen Leehey; James Bourgeois; John Gould; Lin Zhang; Andreea Seritan; Elizabeth Berry-Kravis; John Olichney; Joshua W Miller; Amy L Fong; Randall Carpenter; Cathy Bodine; Louise W Gane; Edgar Rainin; Hillary Hagerman; Paul J Hagerman
Journal:  Clin Interv Aging       Date:  2008       Impact factor: 4.458

View more
  16 in total

Review 1.  Molecular Pathophysiology of Fragile X-Associated Tremor/Ataxia Syndrome and Perspectives for Drug Development.

Authors:  Teresa Botta-Orfila; Gian Gaetano Tartaglia; Aubin Michalon
Journal:  Cerebellum       Date:  2016-10       Impact factor: 3.847

Review 2.  The fragile X mental retardation 1 gene (FMR1): historical perspective, phenotypes, mechanism, pathology, and epidemiology.

Authors:  Jim Grigsby
Journal:  Clin Neuropsychol       Date:  2016-06-29       Impact factor: 3.535

3.  Risk Factors for Cognitive Impairment in Fragile X-Associated Tremor/Ataxia Syndrome.

Authors:  Andreea L Seritan; Kyoungmi Kim; Ian Benjamin; Ioana Seritan; Randi J Hagerman
Journal:  J Geriatr Psychiatry Neurol       Date:  2016-09-21       Impact factor: 2.680

Review 4.  Fragile X premutation in women: recognizing the health challenges beyond primary ovarian insufficiency.

Authors:  Luis R Hoyos; Mili Thakur
Journal:  J Assist Reprod Genet       Date:  2016-12-19       Impact factor: 3.412

5.  Addictive substances may induce a rapid neurological deterioration in fragile X-associated tremor ataxia syndrome: A report of two cases.

Authors:  Zukhrofi Muzar; Patrick E Adams; Andrea Schneider; Randi J Hagerman; Reymundo Lozano
Journal:  Intractable Rare Dis Res       Date:  2014-11

Review 6.  Current research, diagnosis, and treatment of fragile X-associated tremor/ataxia syndrome.

Authors:  Zukhrofi Muzar; Reymundo Lozano
Journal:  Intractable Rare Dis Res       Date:  2014-11

Review 7.  Advances in clinical and molecular understanding of the FMR1 premutation and fragile X-associated tremor/ataxia syndrome.

Authors:  Randi Hagerman; Paul Hagerman
Journal:  Lancet Neurol       Date:  2013-08       Impact factor: 44.182

8.  Trajectory and Predictors of Depression and Anxiety Disorders in Mothers With the FMR1 Premutation.

Authors:  Jane E Roberts; Bridgette L Tonnsen; Lindsay M McCary; Amy L Ford; Robert N Golden; Donald B Bailey
Journal:  Biol Psychiatry       Date:  2015-07-31       Impact factor: 13.382

9.  Towards an Understanding of Neuropsychiatric Manifestations in Fragile X Premutation Carriers.

Authors:  Aaron D Besterman; Scott A Wilke; Tua-Elisabeth Mulligan; Stephen C Allison; Randi Hagerman; Andreea L Seritan; James A Bourgeois
Journal:  Future Neurol       Date:  2014-03

10.  Memantine for fragile X-associated tremor/ataxia syndrome: a randomized, double-blind, placebo-controlled trial.

Authors:  Andreea L Seritan; Danh V Nguyen; Yi Mu; Flora Tassone; James A Bourgeois; Andrea Schneider; Jennifer B Cogswell; Kylee R Cook; Maureen A Leehey; Jim Grigsby; John M Olichney; Patrick E Adams; Wendi Legg; Lin Zhang; Paul J Hagerman; Randi J Hagerman
Journal:  J Clin Psychiatry       Date:  2014-03       Impact factor: 4.384

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.